Skip to Content

Fresenius Medical Care AG ADR

FMS: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$72.00QwxbqBhbp

Fresenius Medical Care's Outlook Challenged by Obesity Drug Expansion

Business Strategy and Outlook

Fresenius Medical Care treats end-stage renal disease patients through its dialysis clinic network, medical technology, and care coordination activities. Its strengths in these related areas help Fresenius maintain the leading global position in this market. After pandemic conditions recede, we expect the company to benefit from decent demand in developed markets, such as the U.S., and even faster expansion in emerging markets, such as China, in the long run. With global ESRD patient growth expected to remain in the low to mid-single digits in the long run, we expect top-line growth for Fresenius to grow at a similar pace during the next five years, if it can get past current inflationary and other challenges.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of FMS so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center